Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
3
institutions
Market cap
$62.3B
1,449M shares
52-week range
$42.20 – $105.65
4% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
P/S (TTM)
3.2
EV / FCF (TTM)
21.8
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
www.bostonscientific.comNo one on the platform currently holds BSX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 3,152,005 | $197.8M |
| The Baupost Groupas of 2026-03-31 | 104,655 | $6.6M |
No one on the platform has traded BSX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.8% | 6.9% | — | — | — | |
| Rev. Growth % | 19.9% | 15.2% | ||||
| Profit Margin % | 14.4% | 10.2% | 11.6% | |||
| Free Cash Flow Margin % | 18.2% | 12.9% | 10.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +1.2% on the P/E track.
At today's price, your expected annual return is +6.6% on the P/E track.
At today's price, your expected annual return is +12.3% on the P/E track.
| 76,992 |
| $4.8M |
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $21.3B | +6.2% | $3.29 | $3.18–$3.36 | 13.7× | 15 |
| 2027 | $22.2B | +4.4% | $3.42 | $3.32–$3.71 | 13.2× | 16 |
| 2028 | $23.8B | +7.0% | $3.79 | $3.61–$4.09 | 11.9× | 7 |
| 2029 | $25.7B | +8.2% | $4.14 | $4.00–$4.51 | 10.9× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $0.83 | $0.86 | +3.0% |
| 2026-04-22 | $0.79 | $0.80 | +1.5% |
| 2026-02-04 | $0.78 | $0.80 | +2.4% |
| 2025-10-22 | $0.71 | $0.75 | +5.0% |
| 2025-07-23 | $0.72 | $0.75 | +3.4% |
| 2025-04-23 | $0.67 | $0.75 | +11.4% |
| 2025-02-05 | $0.66 | $0.70 | +6.5% |
| 2024-10-23 | $0.59 |
| $0.63 |
| +7.1% |
| $181.8B |
| — |
| HCAHCA Healthcare, Inc. | $425.49 | -0.34% | $92.1B | — |
| MCKMcKesson Corporation | $910.95 | +3.34% | $106.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$BSX Share Price: $45.05 Contract Selected: Oct 09, 2026 $45 Calls Buy Zone: $1.47 – $1.81 Target Zone: $2.36 – $2.89 Potential Upside: 52% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
$BSX Interesting..... https://x.com/pdicarlotrader/status/2099601977164362010?s=20
View on StockTwits ↗
$BSX #BSX Bounced on long term support of 42.67, Today we GAPPED UP and is started a Bullish Harami on the Weekly chart. We have resistance at 45.16 but most likely go to 46.67 then next week go higher towards 49.15 then from there form a inverse H&S on that 49 area as the neckline, where we can potentially fire up towards 52-54 after that right shoulder fills out. But we are at the bottom of the inverse H&S and the Bullish harami, so ti will takes some time for 54, so lets watch out for 46-48 then 49 for now #OTWSWatchlist
View on StockTwits ↗
$BSX should be trading around $60-$62 not $45!! It’s been overdone for a while now‼️ all bad news priced in now. $70-$75 by the end of 2027 folks. This will be a nice turnaround by the end of next year✅
View on StockTwits ↗
$BSX $TTD big money flowed out of AI stocks into software and healthcare today
View on StockTwits ↗
$BSX I'm calling bottom right here, unless macro factors pull it lower
View on StockTwits ↗
$BSX Will this be at least $10 a share higher by the time the PEN deal closes??
View on StockTwits ↗
$BSX im glad I dumped this and started accumulating $APP smart decision to bail above 51
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.